The ultimate objective of my research program is the development of therapeutic agents which specifically block the induction of prostate cancer invasion by the sequences of plasma fibronectin, a ubiquitous, soluble component of the blood, lymph and interstitial fluid. A Prostate SPORE Faculty Development Grant supported research in my laboratory whose goal was to identify the plasma fibronectin (pFn) sequence which functioned to elicit the invasion of selectively permeable basement membranes by metastatic prostate carcinoma cells under serum-free conditions. With this support, we identified the invasion-inducing sequence as the PHSRN """"""""synergy sequence"""""""" located in the ninth model of the pFn cell-binding domain. Based on the structure of this sequence, a potent PHSRN inhibitor, the PHSCN peptide was devised. This peptide exhibited log-linear anti-invasive dose response behavior, and eliminated metastatic human DU 145 and rat MLL prostate carcinoma invasion in vitro at concentrations less than 1 microgram per ml. When intravenous doses of the PHSCN peptide were employed to treat groups 10 rats injected with MatLyLu (MLL) metastatic Dunning rat prostate carcinoma cells, the numbers of lung metastases, the masses of intraperitoneal metastatic tissue, and the growth of MLL tumors at their injection sites were reduced very significantly without significant toxic or immunosuppressive effects. This application proposed to define the structure activity relationship for PHSRN invasion-promoting sequence and for its PHSCN inhibitor in vitro employing human or rat prostate carcinoma cell lines like DU 145 or MLL, and serum-optional SU-ECM invasion substrates. This application also proposes to define optimal strategies for utilizing the most active invasion inhibitors as suppressors of prostate cancer invasion and metastasis in rats injected with MLL or less aggressive rat prostate cancer cells. The treatment strategies developed will also be extended to human prostate cancer cells injected into immuno-deficient nude mice.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA069568-05
Application #
6203371
Study Section
Project Start
1999-08-09
Project End
2003-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Rye, Morten Beck; Bertilsson, Helena; Andersen, Maria K et al. (2018) Cholesterol synthesis pathway genes in prostate cancer are transcriptionally downregulated when tissue confounding is minimized. BMC Cancer 18:478
Xie, Yuanyuan; Cao, Zhen; Wong, Elissa Wp et al. (2018) COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. J Clin Invest 128:1442-1457
Singhal, Udit; Wang, Yugang; Henderson, James et al. (2018) Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Mol Cancer Res 16:643-654
Wang, Xiaoju; Qiao, Yuanyuan; Asangani, Irfan A et al. (2017) Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. Cancer Cell 31:532-548.e7
Blattner, Mirjam; Liu, Deli; Robinson, Brian D et al. (2017) SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer Cell 31:436-451
Dai, Xiangpeng; Gan, Wenjian; Li, Xiaoning et al. (2017) Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat Med 23:1063-1071
Lin, Ke-Chih; Torga, Gonzalo; Wu, Amy et al. (2017) Epithelial and mesenchymal prostate cancer cell population dynamics on a complex drug landscape. Converg Sci Phys Oncol 3:
Chen, Weiqiang; Allen, Steven G; Reka, Ajaya Kumar et al. (2016) Nanoroughened adhesion-based capture of circulating tumor cells with heterogeneous expression and metastatic characteristics. BMC Cancer 16:614
Hu, Shuhuan; Liu, Guangyu; Chen, Weiqiang et al. (2016) Multiparametric Biomechanical and Biochemical Phenotypic Profiling of Single Cancer Cells Using an Elasticity Microcytometer. Small 12:2300-11
Piert, Morand; Montgomery, Jeffrey; Kunju, Lakshmi Priya et al. (2016) 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies. J Nucl Med 57:1065-70

Showing the most recent 10 out of 527 publications